tradingkey.logo
tradingkey.logo
Search

Karyopharm Therapeutics Inc

KPTI
Add to Watchlist
0.832USD
+0.352+73.33%
Close 10-28 16:00(ET)
18.87MMarket Cap
LossP/E TTM
After-hours 19:59 (ET)0.800USD-0.031-3.73%

Today

+73.33%

5 Days

+96.23%

1 Month

-48.64%

6 Months

-90.33%

Year to Date

-88.70%

1 Year

-86.86%

Key Figures

0.456Open
0.909High
1.65MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
7.28%Turnover Ratio
0.480Prev. Close
0.456Low
1.11MTurnover
LossP/E Static
-0.06P/B
0.00%Div Yield TTM
-150.48%ROA
10.99052wk High
239.56Volume Ratio
-76.42MNet Profit
22.68MShares
-16.1748EPS TTM
0.83Beta
--ROE
0.31052wk Low
99.38%Amplitude
96.45%Gross Margin
18.87MMarket Cap
-12.16Reward/Risk
9.35%Risk Rate
Recent
Transcripts
More news coming soon, stay tuned...

Karyopharm Therapeutics Inc's Score

-0.02vs previous score
Forecast8.00
Financial Health7.48
Technical7.12
Valuation Dimensions9.70
Institutional Confidence5.00
Risk Assessment1.57

Media Coverage

Coverage Level

Very Low
Very High
Neutral

Analyst Rating

Strong Buy
Buy
Hold
Sell
Strong Sell
BuyCurrent Rating
7.250Target Price
+1403.84%Upside Space
Current Rating2026-102026-092026-082026-072026-062026-052026-042026-03
Strong Buy11122222
Buy33344444
Hold11211111
Sell00000000
Strong Sell00000000

Karyopharm Therapeutics Inc Technical Analysis

1m
5m
15m
30m
1h
2h
4h
D
W
M
1m
5m
15m
D
Technical Indicators
Neutral
Summary
Neutral
Moving Average
Neutral

Karyopharm Therapeutics Inc Latest Earnings Call Transcripts

Karyopharm (KPTI) Q2 2026 Earnings Call: Selinexor sNDA and Liquidity Focus

Karyopharm’s Q2 2026 earnings call covered $33.4 million in revenue, an August selinexor sNDA target, reaffirmed guidance and near-term liquidity risk.

Financial Indicators

Currency: USD
Quarterly
Quarterly
Annual
Relevant data have not been disclosed by the company yet.
Currency: USD
Quarterly
Quarterly
Annual
Relevant data have not been disclosed by the company yet.

Earnings

Next reporting date
--
Reporting Period
2026Q2
Earnings / Forecast
-2.32/-1.28
Revenue / Forecast
33.43M/32.19M

Karyopharm Therapeutics Inc Profile

SectorPharmaceuticals
Ticker SymbolKPTI
Number of employees279
CountryUnited States of America

Ownership

ShareholdersProportion
Commodore Capital LP8.65%
RA Capital Management, LP8.51%
T. Rowe Price Investment Management, Inc.6.62%
J. Wood Capital Advisors LLC3.48%
Shareholder TypesProportion
Hedge Fund30.88%
Investment Advisor14.61%
Venture Capital9.19%
Investment Advisor/Hedge Fund4.42%

FAQs

What is the current price of Karyopharm Therapeutics Inc (KPTI)?

The current price of Karyopharm Therapeutics Inc (KPTI) is 0.83.

What is the symbol of Karyopharm Therapeutics Inc?

The ticker symbol of Karyopharm Therapeutics Inc is KPTI.

What is the 52-week high of Karyopharm Therapeutics Inc?

The 52-week high of Karyopharm Therapeutics Inc is 10.99.

What is the 52-week low of Karyopharm Therapeutics Inc?

The 52-week low of Karyopharm Therapeutics Inc is 0.31.

What is the market capitalization of Karyopharm Therapeutics Inc?

The market capitalization of Karyopharm Therapeutics Inc is 18.87M.

Is Karyopharm Therapeutics Inc (KPTI) currently rated as Buy, Hold, or Sell?

According to analysts, Karyopharm Therapeutics Inc (KPTI) has an overall rating of Buy, with a price target of 7.25.

What is the Earnings Per Share (EPS TTM) of Karyopharm Therapeutics Inc (KPTI)?

The Earnings Per Share (EPS TTM) of Karyopharm Therapeutics Inc (KPTI) is -16.17.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.